Qazi Corner, Edition 4: Vonoprazan, Etrasimod, SEQUENCE, and Celiac Guidelines
The final quarterly issue of the year touches on head-to-head trial data, a new treatment for erosive esophagitis, an ulcerative colitis agent, and the latest ACG recommendations for Celiac disease.e.
Celiac Disease ACG Guidelines Update
An expert reviews the updated recommendations of the American College of Gastroenterology guidelines on the evaluation and management of celiac disease.
Vonoprazan for the Treatment of Erosive Esophagitis: A Randomized Controlled Trial
While more studies are needed to ensure the safety of long-term therapy with PCABs, this study establishes a role for the use of vonoprazan in the healing and maintenance of healing in patients with erosive esophagitis.
SEQUENCE: Comparing Risankizumab to Ustekinumab in Crohn’s Disease
Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.
Etrasimod: A New Oral Treatment Option for Ulcerative Colitis
The S1PR modulators are currently positioned to serve as a great treatment option for patients with moderate disease who are hesitant to escalate to a biologic treatment.
Qazi Corner, Edition 3: Upadacitinib, Smoking Cessation, FIT Screening, and More
This quarter's issue highlights expert perspective on systemic and invasive care for gastric disease, the ELEVATE model, and fecal immunochemical testing for colorectal cancer.
Bariatric Surgery is Associated with Reduced Risk of Pancreatic Cancer: Analysis of a US National Database
A history of bariatric surgery was associated with up to 50% reduced risk of PDAC among a national cohort.
An Assessment of an EHR-Assisted Tobacco Treatment Model for GI Patients: Takeaways from ELEVATE
How an outpatient-based smoking cessation model may come to aid other health systems' gastroenterology patients.
Sessile Serrated Polyp Detection Rate in Asymptomatic Average Risk Individuals with Positive Fecal Immunochemical and Multitarget Stool DNA Test: A Systematic Review And Meta-Analysis
Investigators assess the detection rate of FIT and FIT-DNA among average-risk colorectal cancer screening individuals.
A Review of Upadacitinib in Crohn’s Disease: A Promising JAK1 Inhibitor
The Cleveland Clinic fellow explains why is upadacitinib is an essential tool in treating Crohn’s disease, especially in those who have previously failed conventional or biologic therapies.
Screening and Management Guidance Reviews Highlight Issue 2 of Qazi Corner
From new ACG GERD guidelines to the efficacy of colonoscopies, our latest issue addresses topics changing practice and stirring conversation.
A Deep Dive Into the 2022 ACG GERD Guideline Update
A review of changes to clinical, dietary and screening strategies for patients with GERD.
The NordICC Trial: Analyzing the Effectiveness of a Colonoscopy Screening Program at Reducing Colorectal Cancer Incidence and Mortality
A northern Europe-based trial highlights the potential impact of streamlined and community-supported colonoscopy screening for cancer.
Does Aggressive or Moderate Fluid Resuscitation Better Treat Acute Pancreatitis?
A recent randomized controlled trial showed the limitations of either option, despite being a cornerstone of care.
Ustekinumab Versus Adalimumab in Crohn's Disease: Reviewing the Phase 3B SEAVUE Trial
Analysis from a multicenter, randomized, double-blind, parallel group study comparing the drugs as induction and maintenance therapies in biologic-naïve patients.
Upadacitinib: An Evolving Treatment for Ulcerative Colitis
The inhibition of Janus kinase to prevent downstream signaling of proinflammatory cytokines has been shown to be a novel method of treating ulcerative colitis.
Risankizumab: A New Treatment Option for Crohn’s Disease
Risankizumab represents the first ever IL-23 treatment for adult patients with Crohn's disease approved by the FDA.
Extraintestinal Manifestations of Inflammatory Bowel Disease: A Step Toward Standardizing Assessment
Investigators from the Cleveland Clinic standardized diagnostic, follow-up, and treatment targets for 5 major EIMs: peripheral arthritis, axial arthritis, pyoderma gangrenosum, erythema nodosum, and uveitis.
Fatty Pancreas: Is It a Benign Entity?
Investigators assessed the etiology, clinical implications, and long-term outcomes of fatty pancreas.
Introducing The Qazi Corner With Taha Qazi, MD
Here's what you have to look forward to from our new quarterly gastroenterology newsletter.
2 Clarke Drive Cranbury, NJ 08512